BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
July 25, 2024 17:39 ET
|
BioAtla, Inc.
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly...
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
July 23, 2024 08:00 ET
|
BioAtla, Inc.
Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in...
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
June 27, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:05 ET
|
BioAtla, Inc.
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as...
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 14, 2024 16:05 ET
|
BioAtla, Inc.
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for...
BioAtla to Participate in the Citizens JMP Life Sciences Conference
May 08, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
May 07, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
May 06, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:35 ET
|
BioAtla, Inc.
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...